US Patent

US9327028 — Acetylcysteine compositions and methods of use thereof

Method of Use · Assigned to Cumberland Pharmaceuticals Inc · Expires 2031-07-21 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering acetylcysteine to reduce side effects in human patients.

USPTO Abstract

A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.

Drugs covered by this patent

Acetadote (Acetylcysteine) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1839`	—	Acetadote

Patent Metadata

Patent number: US9327028
Jurisdiction: US
Classification: Method of Use
Expires: 2031-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Cumberland Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.